{"name":"Stero Biotechs Ltd.","slug":"stero-biotechs-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CBD","genericName":"CBD","slug":"cbd","indication":"Epilepsy (Dravet syndrome, Lennox-Gastaut syndrome)","status":"marketed"}]}],"pipeline":[{"name":"CBD","genericName":"CBD","slug":"cbd","phase":"marketed","mechanism":"CBD (cannabidiol) modulates endocannabinoid signaling and interacts with multiple receptors including serotonin 5-HT1A, TRPV1, and GPR55 to produce anti-inflammatory, anxiolytic, and analgesic effects.","indications":["Epilepsy (Dravet syndrome, Lennox-Gastaut syndrome)","Chronic pain","Anxiety disorders","Inflammation-related conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNNERBWHBHbU9VdVpiYjloY1VsYVFseGJ0bFlwVXFMcllOWDlmZktQbkt0VmgzdHBSZURxRnFVU0ZVN2dYb19CdDFUREQ5a3RrVkYxWXBIOGRmQTF2aTAweVMtZVlZUVBlX2h4SXZuazNIUnlLQm5RaVl4ZkgxM3lJLVRnTkJ2aEQya2JuSnE1eVpad1Z0V1EyU2ZXcHBiSHdVdmNqc2FLMzJvSEwwZWljU2cyUXNhU09wdWd3UmJoOFpyME5EMEZYRk9xVFNDZzYzMmZEelpEbXJvN0M2QnJxQy13MnZEeUdXUHNrODI4eVdzeWZ1eUhiOA?oc=5","date":"2026-02-13","type":"earnings","source":"scanx.trade","summary":"Medicamen Biotech Reports Q3 FY26 Results; Board Reconstitutes Committees Following Director Tenure Completion - scanx.trade","headline":"Medicamen Biotech Reports Q3 FY26 Results; Board Reconstitutes Committees Following Director Tenure Completion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNNC10R0ZJNnpuOGRyQ3FpV1BoRXJVQWlTSXhDa2pFcVBsTTlORE9BLXY5QzZLWlhMa1Q3VE0tV0Z2LWh6Q003aFRSSms1d19YQUMtVG1LSHdmYlZBclREbVR6UU9PTWIzZ3U4b0NUdWh5MnBYdjlKbkVJMVhzVFRMblJEOTdseEZITkpwaGJpQ2d5Vl9OMld0YUpCOExvSEo0UmxmeF9vN0hzU0ZmRkd6WmR6Um9XeTEyWmU2V0diMmFIYWZwZUN0X3RfbmhqLWVDc3dDeERTMHA1M0otYnRINVZzb3Y?oc=5","date":"2026-01-07","type":"regulatory","source":"scanx.trade","summary":"Medicamen Biotech Receives EU Approval for Paracetamol Registration from Denmark with XGX Pharma - scanx.trade","headline":"Medicamen Biotech Receives EU Approval for Paracetamol Registration from Denmark with XGX Pharma","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOVlhrTUVoeExFSzh2cUZfNEw2UUFvYUViOVNsNjJ3Zll1Vlo5U0ExX19ic0tWa2xIVWFybmhmOUZleS1lZTlacU9lMmVpQzllSGlNWWpNU0hFc09PMmUxWGg5Yl93eDBmM2JGZUZfUmJiUHcxRFZWLU0waThSQ3VhNlJMdURDTkJTSlctcW9tNXo1N2JpUGZrQ0lOWHFobnBLX3VxV1U3TWdzSXdJbHpQc1hLVFFLbkNhVEpNWGhxOGNjQVFab0t1NHJaZ2lxU3dmN3kxcGJvWEsxRW1JU2xfVm9sbkVOZ0stSFJv?oc=5","date":"2025-06-10","type":"trial","source":"GlobeNewswire","summary":"Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire","headline":"Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPMGhPdGxVQ2ZhVEN3MkFUXy1rb0VSR3Y3Y3FuWXhzVWdMVmVkdkpHZnZXMWRHcnAyeEVUTVN0X09tRDA3bVdtR2M4M1lVNFo5UXNWWjEzRkNoSjBJS0llaXZNV0VSaEFqOFpvcjFoa0paYkNCZi1HdGR4OHBVY2Y4eGFTNWNLUzFkaHgydjNSRkxiNDdsU2c1WWl1elI0aUNfRmh2c0xYMENfZ0oteDk5c1hRY0swVjVkMjJaMF93eGpSaTBnVFJETjNxMFpSOUx0c1Z5N0VBdlFjYzlpNnhrcGxBbFAzZ20ycVE?oc=5","date":"2025-04-15","type":"pipeline","source":"PR Newswire","summary":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire","headline":"Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE96SjVqUUU4dmluM2NlV3dXOE80STZBTEowS2wzSWtIY0NVUFBNd0tEOHhaZmdTTzZFenZxWlhMR3BuTTU3RzhidlZ3SlNrRzJleVdlSl9qVGVHMGNUNERialdtekt0Y3RQVlBYdNIBckFVX3lxTE8wQzg2NE5vZWlTVXpHQ2ZRT3h6TkZXZm15QjdNNnkwZjNIUGpBSXh4RFdLNEdjcmxNWHBTWmdEcG1RM3dEY3J2R0dSN2JHSHFJU2V1d1Q5YkdGQUxGTUc3SzBoV2tJQWN2dXJaODZoVXpUZw?oc=5","date":"2023-10-17","type":"pipeline","source":"housing.com","summary":"Top biotech companies in Hyderabad - housing.com","headline":"Top biotech companies in Hyderabad","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9qaUQtN1d4Q1lpUm5Nbmx5THI2QmhzMHNYU01JcjdnclZQWUVCRWVpay1XWHkxT2dRMENXc3A1OUI0b1p4ZzI1M3AzSDMxUHpDVDZ1VDl6MEJIX3p0X09LVnhRdnB0cEY0NDViM1JR?oc=5","date":"2023-03-14","type":"pipeline","source":"KED Global","summary":"S.Korean biotech NKMax’s unit aims for US IPO - KED Global","headline":"S.Korean biotech NKMax’s unit aims for US IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPWnZUNGh4Z0hkbmZuVEhvVjZuU29RWXVWOW5yaW42UnluaXo1MVBCNjdkUUEtTXVFMW1EX2dVaTJBLXFHZDNHUC1UOWYwcllfZzNsQVdtQjg5TjdNYWNaemRmM1F4WGVFak10dWFwTXhTc3V4RjhOOUEwMjlaSmJMYVV3RDl0UmdLUlczTUV2TjhVUHhURHFobjN2MUZhVy1Jb19YN0lDbFZQUk43bldYcG8zQVVERTRpNV93MjdnYWdSaFR4ZWZkREtFTW5UQm9UdlJEaXlJNDNhOXdfTXpTMGxPbTE3d1lMeDYzWkR2bEdpb3FZaVYtRmdxeFphN1hZc0V3N3FESlFiUG1VWEdNOVZKZV9nWW9jODc1MUs0R0pZWGxhVGZrTFhPSDJyZw?oc=5","date":"2022-04-25","type":"trial","source":"PR Newswire","summary":"Chronic Spontaneous Urticaria Market Is Anticipated to Progress at a CAGR of 14.96% in the 7MM for the Study Period of 2019-32, Estimates DelveInsight - PR Newswire","headline":"Chronic Spontaneous Urticaria Market Is Anticipated to Progress at a CAGR of 14.96% in the 7MM for the Study Period of 2","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}